{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-000779","form_type":"8-K","ticker":"AGEN","cik":"0001098972","company_name":"AGENUS INC","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.935520+00:00","generated_at":"2026-06-15T08:06:38.956012+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Agenus Q1 net loss $70.9M; botensilimab combo shows 63% 12-month OS in colorectal cancer","bullets":["Revenue $22.9M, net loss $70.9M ($0.22 EPS) vs loss $50.6M ($0.19 EPS) year ago.","Cash & investments $189.2M at March 31; raised $13.6M in ATM sales post-quarter.","Botensilimab/balstilimab: 63% 12-month OS in non-MSI-H CRC (vs 25% SOC); 33% ORR in platinum-resistant ovarian cancer.","FDA granted Fast Track for botensilimab/balstilimab in non-MSI-H/dMMR mCRC without active liver metastases.","Distributed ~5M MiNK shares (NASDAQ: INKT) as dividend to AGEN shareholders on May 1, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-000779","json":"https://secwatch.observer/filing/0001157523-23-000779.json","markdown":"https://secwatch.observer/filing/0001157523-23-000779.md","text":"https://secwatch.observer/filing/0001157523-23-000779.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1098972/000115752323000779/0001157523-23-000779-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1098972/000115752323000779/a53395899.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:06:38.956012+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a3b66f583a8b0e790df519923a0bde482673ba90","claim":"AGENUS INC reported the first quarter ended March 31, 2023 results: revenue $22.9 million, net income $70.9 million, EPS $0.22 per share.","evidence_excerpt":"For the first quarter ended March 31, 2023, we recognized revenue of $22.9 million and incurred a net loss of $70.9 million (including non-cash expenses of $24.9 million) or $0.22 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1098972/000115752323000779/0001157523-23-000779-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$22.9 million"},{"label":"Net income","value":"$70.9 million"},{"label":"EPS","value":"$0.22 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}